CONAVI MEDICAL CORP (CNVI.CA) Stock Price & Overview

TSX-V:CNVI • CA2059531020

Current stock price

0.37 CAD
-0.02 (-5.13%)
Last:

The current stock price of CNVI.CA is 0.37 CAD. Today CNVI.CA is down by -5.13%. In the past month the price decreased by -7.5%. In the past year, price decreased by -37.29%.

CNVI.CA Key Statistics

52-Week Range0.35 - 0.7
Current CNVI.CA stock price positioned within its 52-week range.
1-Month Range0.36 - 0.415
Current CNVI.CA stock price positioned within its 1-month range.
Market Cap
38.291M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.25
Dividend Yield
N/A

CNVI.CA Stock Performance

Today
-5.13%
1 Week
-7.50%
1 Month
-7.50%
3 Months
-17.78%
Longer-term
6 Months -40.32%
1 Year -37.29%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

CNVI.CA Stock Chart

CONAVI MEDICAL CORP / CNVI Daily stock chart

CNVI.CA Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to CNVI.CA. When comparing the yearly performance of all stocks, CNVI.CA is a bad performer in the overall market: 93.68% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CNVI.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to CNVI.CA. CNVI.CA may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CNVI.CA Earnings

Next Earnings DateMay 26, 2026
Last Earnings DateFeb 26, 2026
PeriodQ1 / 2026
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

CNVI.CA Forecast & Estimates

5 analysts have analysed CNVI.CA and the average price target is 1.02 CAD. This implies a price increase of 175.68% is expected in the next year compared to the current price of 0.37.

For the next year, analysts expect an EPS growth of 50% and a revenue growth -34.34% for CNVI.CA


Analysts
Analysts80
Price Target1.02 (175.68%)
EPS Next Y50%
Revenue Next Year-34.34%

CNVI.CA Groups

Sector & Classification

Index Membership

CNVI.CA Financial Highlights

Over the last trailing twelve months CNVI.CA reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS increased by 76.95% compared to the year before.


Income Statements
Revenue(TTM)706.00K
Net Income(TTM)-16.19M
Industry RankSector Rank
PM (TTM) N/A
ROA -164.51%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%79.93%
Sales Q2Q%-97.48%
EPS 1Y (TTM)76.95%
Revenue 1Y (TTM)-91.82%

CNVI.CA Ownership

Ownership
Inst Owners0.24%
Shares103.49M
Float68.85M
Ins Owners0.16%
Short Float %N/A
Short RatioN/A

About CNVI.CA

Company Profile

CNVI logo image Conavi Medical Corp. engages in the designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. The company is headquartered in Toronto, Ontario. The company went IPO on 2008-04-28. The firm is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. The Novasight Hybrid System is intended for intravascular imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. Its Novasight Hybrid System combines both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. Hybrid IVUS and OCT imaging provides additional information over single modality imaging in complex lesions. The versatility of hybrid imaging is useful for a variety of complex percutaneous coronary interventions (PCIs), including situations where the customer may want to image large ostial lesions with IVUS but also use OCT for diseased distal lesions and/or stent assessment.

Company Info

IPO: 2008-04-28

CONAVI MEDICAL CORP

76 Berkeley Street

TORONTO ONTARIO CA

Employees: 4

CNVI Company Website

CNVI Investor Relations

Phone: 14165487522

CONAVI MEDICAL CORP / CNVI.CA FAQ

What does CNVI do?

Conavi Medical Corp. engages in the designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. The company is headquartered in Toronto, Ontario. The company went IPO on 2008-04-28. The firm is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. The Novasight Hybrid System is intended for intravascular imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. Its Novasight Hybrid System combines both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. Hybrid IVUS and OCT imaging provides additional information over single modality imaging in complex lesions. The versatility of hybrid imaging is useful for a variety of complex percutaneous coronary interventions (PCIs), including situations where the customer may want to image large ostial lesions with IVUS but also use OCT for diseased distal lesions and/or stent assessment.


What is the stock price of CONAVI MEDICAL CORP today?

The current stock price of CNVI.CA is 0.37 CAD. The price decreased by -5.13% in the last trading session.


What is the dividend status of CONAVI MEDICAL CORP?

CNVI.CA does not pay a dividend.


What is the ChartMill rating of CONAVI MEDICAL CORP stock?

CNVI.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


Would investing in CONAVI MEDICAL CORP be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CNVI.CA.


Can you provide the growth outlook for CONAVI MEDICAL CORP?

The Revenue of CONAVI MEDICAL CORP (CNVI.CA) is expected to decline by -34.34% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


When does CONAVI MEDICAL CORP (CNVI.CA) report earnings?

CONAVI MEDICAL CORP (CNVI.CA) will report earnings on 2026-05-26.